Comparing the Efficacy of Conservative Treatment With Minimally Invasive Surgery in the Treatment of Rib Fractures

January 17, 2021 updated by: Li Yang, Shanghai 6th People's Hospital

Comparing the Efficacy of Conservative Treatment With Minimally Invasive Surgery in the Treatment of 2-4 Displaced Rib Fractures:A Prospective Randomized Controlled Study

Open, randomized, parallel controlled prospective clinical study design was used in this study.Subjects were patients with 2-4 displaced non-flail rib fractures.Operation group (Group 1) : minimally invasive internal fixation operation group under spontaneous breathing anesthesia.In the operation group of minimally invasive internal fixation under autonomic respiratory anesthesia, the fracture was determined preoperatively by chest CT+ three-dimensional reconstruction of the ribs, and the optimal incision location was determined. The fracture was exposed through as many small incisions as possible, and fixed with titanium plate or clon-type plate. During the operation, the autonomic respiratory anesthesia and paraviral nerve block technology was adopted.In the conservative group (group 2), routine treatment measures such as analgesia and chest strap fixed were adopted.The purpose of this study was to evaluate the safety, feasibility, and efficacy of minimally invasive and conservative treatment for rib fractures with different Numbers of displaced ends.

Study Overview

Detailed Description

An open, randomized, parallel controlled prospective clinical study design type was used in this study. Subjects were patients with two to four displaced non-flail chest fractures of the ribs. Operation group (Group 1) : minimally invasive internal fixation operation group under spontaneous breathing anesthesia. In the operation group of minimally invasive internal fixation under autonomic respiratory anesthesia, the fracture was determined preoperatively by chest CT+ three-dimensional reconstruction of the ribs, and the optimal incision location was determined. The fracture was exposed through as many small incisions as possible, and fixed with titanium plate or clon-type plate. During the operation, the autonomic respiratory anesthesia and paraviral nerve block technology was adopted. In the conservative group (group 2), routine treatment measures such as analgesia, hemostasis and chest band fixation were adopted. The effects of the two treatments on lung function, pain index, complications and QoL were evaluated. It provides theoretical basis for the treatment of rib fracture

Study Type

Interventional

Enrollment (Anticipated)

238

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 70 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Unilateral thoracic trauma, fractured ends of rib fractures displaced 2-4 places
  2. Displaced fracture(CT image shows double displacement of bone cortex) located in the 3rd to 10th rib
  3. The number of broken ends of displaced fractures is greater than that of undisplaced fractures
  4. The length of time from injury to hospitalization <24 hours
  5. Age range(18-70)
  6. ASA grade I-II
  7. BMI < 30
  8. Preoperative partial arterial oxygen pressure >60mmHg, partial arterial carbon dioxide pressure <50mmHg

Exclusion Criteria:

  1. Difficult airway
  2. History of esophageal reflux
  3. Myasthenia gravis
  4. Abnormal coagulation system
  5. History of gastrointestinal ulcer or bleeding
  6. History of anaesthesia related drug allergy

A history of asthma or chronic obstructive emphysema

8. Women during pregnancy

9. Flail chest

10. Combined with severe craniocerebral trauma and external abdominal injuries

11. Recent use of clopidogrel, warfarin and aspirin seriously affects blood clotting

12. Self-administered analgesics after injury

13.Massive hemopneumothorax requires emergency surgery

14. Patients who cannot tolerate surgery

-

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: surgical treatment
Minimally invasive internal fixation under spontaneous respiratory anesthesia and analgesic treatment and chest strap fixation
surgical treatment and Conservative treatment
Conservative treatment
EXPERIMENTAL: Conservative treatment
analgesic treatment and chest strap fixation
Conservative treatment

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage improvement of lung function FEV1(Forced expiratory volume in one second)
Time Frame: FEV1%(One week after treatment)-FEV1%(Admitted)
FEV1(Forced expiratory volume in one second),FEV1% :percentage of the expected value
FEV1%(One week after treatment)-FEV1%(Admitted)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage improvement of lung function FVC
Time Frame: FVC%(One week after treatment)-FVC%(Admitted)
FVC(forced vital capacity),FVC%:percentage of the expected value
FVC%(One week after treatment)-FVC%(Admitted)
Percentage improvement of lung function PEF
Time Frame: PEF%(One week after treatment)-PEF%(Admitted)
PEF(peak expiratory flow ),PEF%:percentage of the expected value
PEF%(One week after treatment)-PEF%(Admitted)
Pain index
Time Frame: Admitted;One week after treatment;One month after treatment;Three month after treatment;Half a year;One year
visual analogue scale,VAS(0-10)0:no pain;10:severe pain
Admitted;One week after treatment;One month after treatment;Three month after treatment;Half a year;One year
Pleural effusion
Time Frame: Admitted;One week after treatment;One month after treatment;Three month after treatment;Half a year;One year
Measured by chest CT
Admitted;One week after treatment;One month after treatment;Three month after treatment;Half a year;One year
Mortality rate
Time Frame: Admitted;One week after treatment;One month after treatment;Three month after treatment;Half a year;One year
Deaths associated with this study
Admitted;One week after treatment;One month after treatment;Three month after treatment;Half a year;One year
Length of hospital stay
Time Frame: Admitted;One week after treatment;One month after treatment;Three month after treatment;Half a year;One year
Length of hospital stay
Admitted;One week after treatment;One month after treatment;Three month after treatment;Half a year;One year
Cost of treatment
Time Frame: One year
Sum of all treatment costs
One year
Chronic pain
Time Frame: Three month after treatment;Half a year;One year
Pain lasting more than three months(It is suggested in the related article that pain lasting more than 3 months is chronic pain)visual analogue scale,VAS(0-10)0:no pain;10:severe pain
Three month after treatment;Half a year;One year
Quality of Life score
Time Frame: One week after treatment;One month after treatment;Three month after treatment;Half a year;One year
The Barthel index of ADL
One week after treatment;One month after treatment;Three month after treatment;Half a year;One year
Time to resume routine work
Time Frame: One week after treatment;One month after treatment;Three month after treatment;Half a year;One year
Time to resume routine work
One week after treatment;One month after treatment;Three month after treatment;Half a year;One year
Duration of analgesic medication
Time Frame: intraoperative;One week after treatment;One month after treatment;Three month after treatment;Half a year;One year
Duration of analgesic medication
intraoperative;One week after treatment;One month after treatment;Three month after treatment;Half a year;One year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Yi Yang, PHD, Shanghai 6th People's Hospital
  • Study Chair: Zongli Gao, PHD, Shanghai 6th People's Hospital
  • Study Chair: Yonghong Zhao, PHD, Shanghai 6th People's Hospital
  • Study Chair: Weiming Wu, PHD, Shanghai 6th People's Hospital
  • Study Chair: Weigang Zhao, PHD, Shanghai 6th People's Hospital
  • Study Chair: Tiancheng Zhao, PHD, Shanghai 6th People's Hospital
  • Study Chair: Xiang Guo, PHD, Shanghai 6th People's Hospital
  • Study Chair: Lei Wang, PHD, Shanghai 6th People's Hospital
  • Study Chair: Weiwei He, PHD, Shanghai 6th People's Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ANTICIPATED)

March 1, 2021

Primary Completion (ANTICIPATED)

June 10, 2023

Study Completion (ANTICIPATED)

June 30, 2024

Study Registration Dates

First Submitted

August 15, 2020

First Submitted That Met QC Criteria

September 7, 2020

First Posted (ACTUAL)

September 9, 2020

Study Record Updates

Last Update Posted (ACTUAL)

January 20, 2021

Last Update Submitted That Met QC Criteria

January 17, 2021

Last Verified

January 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • ynlc201908

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

The data will not be Shared with other researchers

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Surgery--Complications

Clinical Trials on surgical treatment

3
Subscribe